This is for information of all concerned that the Board of Directors of the Company in their meeting held on 30 April, 2013 at 3.30 p.m. has approved the audited Financial Statements for the year ended 31 December, 2012. 15% stock dividend has been recommended and the AGM and record date has been fixed.

pdf Press Releases 1 May 2013

Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol: BXP), today announces its unaudited financial results for the third quarter and nine months ended 30 September 2012 in compliance with the requirements from the Bangladesh SEC

pdf Open/ Download

Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) today announces its results for the half year to 30 June 2011.

Highlights

Half year financial highlights

  • Net sales increased by 22.7% to Bangladesh Taka ("BDT") 3,642.3m / £30.5m (2010: BDT 2,968.7 m / £27.3m)
    • Domestic sales increased 22.8% to BDT 3,468.8m / £29.1m (H1 2010: BDT 2,825.9m / £26.0m)
    • Export sales increased 21.6% to BDT 173.5m / £1.5m (H1 2010: BDT 142.7m / £1.3m)
  • Profit before tax increased by 9.6% to BDT 764.5m / £6.4m (H1 2010: BDT 697.3m / £6.4m)
  • EPS increased by 7.9% to BDT 2.72 / 2.3 pence (2010: BDT 2.52 / 2.3 pence)

Second quarter highlights

  • Net sales increased by 20% to BDT 1,970.6m / £16.5m (2010: BDT1,642.0m / £15.1m)
  • Profit before tax increased by 21.6% to BDT 461.4m / £3.9m (2010: BDT 379.3m / £3.5m)

Operational highlights

  • 10 new products registered in overseas markets
  • Launched 21 new products across different therapeutic classes
  • Plant and Machinery for the New MDI (Metered Dose Inhaler) facility installed and commissioned, trial production scheduled August 2011

Post-period events

  • Received GMP (Good Manufacturing Practices) accreditation from Austrian regulatory authority for Oral Solid and Sterile Eye Drop Facilities
    • Approval recognized throughout European Union (EU)

This is for information of the valued Shareholders of the Company that the Board of Directors in their meeting held on 28 April, 2011 at 3.30 p.m. has decided in regard to 35th Annual General Meeting (AGM) of the Shareholders of the Company for the year ended 31st December, 2010 as follows:

pdf Press Releases 28 April 2011

We are pleased to present the un-audited Financial Statements of Beximco Pharmaceuticals Ltd. for the first quarter ended March 31, 2011 as per Securities and Exchange Commission Notification No. SEC/CMRRCD/2008-183/Admin/03-34 dated September 27, 2009.

pdf Open/ Download